Drug Trial Radar · NCT03943264
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's
Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 20, 2019
Primary completion
Jun 30, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- Inmune Bio, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Alzheimer's Association
- First posted
- May 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.
Conditions
- Alzheimer Disease
Interventions
XPro1595Drug
XPro1595 will be delivered by subcutaneous injection once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595Time frame: 12 weeks
- The percentage of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595Time frame: 12 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
KaRa MINDS
Macquarie Park, New South Wales, Australia
Mater Medical Research Institute
Brisbane, Queensland, Australia
Central Adelaide Local Health Network
Woodville, South Australia, Australia
Alfred Heath
Melbourne, Victoria, Australia
Eastern Clinical Research Unit
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.